WuXi Biologics sells global rights to cancer antibody to Candid for $925m
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight.
US-based medical device maker Stryker Corporation will acquire Inari Medical Inc., for about $4.9 billion to expand the former’s neurovascular business.
HQ Team January 4, 2025: A new study reveals that genetic testing can identify which antifungal drugs will effectively treat patients with Candida.
HQ Team January 2, 2025: Scientists at the University of California San Diego School of Medicine have made deeper inroads in understanding the.
HQ Team December 28, 2024: A study from Taiwan links the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy, with a potential risk.
The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death.
Humacyte Global, Inc., a US-based bioengineering company, got the US regulator’s nod for its product Symvess, a surgical implant to replace a patient’s.
fizer Inc.’s combination drug to treat a type of metastatic colorectal cancer has been approved by the US drug regulator, according to a.
Vertex Pharmaceuticals Inc.’s Alyftrek drug got clearance from the Food and Drug Administration to expand its treatment for cystic fibrosis in people six.
The US Food and Drug Administration has approved Ionis Pharmaceuticals’ drug to treat a rare and life-threatening genetic disease known as familial chylomicronemia.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com